PDCD1 and neoplasm: For example, inhibiting immune checkpoints such as PD-1, CTLA-4, and TIM-3, alongside CAR-T-cell therapy, have demonstrated increased treatment efficacy in a D270 mouse model, evidenced by better control of tumor growth and extended survival.